tag darzalex 
pharmaphorum
AUGUST 25, 2022
Both bispecifics have arisen out of J&J’s longstanding alliance with Genmab, which also generated anti-CD38 blockbuster Darzalex (daratumumab). Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.
pharmaphorum
JULY 25, 2022
Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under review at the FDA and if approved will slot into J&J’s myeloma therapy portfolio alongside Darzalex (daratumumab) – an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel).
pharmaphorum
MARCH 27, 2022
The KarMMa trial of Abecma involved a similar patient group – treated with at least three lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody such as J&J’s Darzalex (daratumumab) – with an overall response rate of 72% and 28% complete responses.
Expert insights. Personalized for you.
98 
Let's personalize your content